Triple negative breast cancer (TNBC) is an aggressive type of breast cancer that is defined by what it is not. Specifically, TNBC does not express estrogen receptors, progesterone receptors, and does not have overexposed Her-2 receptors. Metastasis is the most common complication, with brain metastasis increasing dramatically with the increase in management of non-brain metastases. Activation of the Wnt signaling pathway is a common feature of TNBC. The Yee lab has been exploring a combinatorial drug approach that crosses the blood brain barrier to target brain metastasis by suppressing Wnt signaling. We have shown that the combination therapy inhibits TNBC tumor growth and decreases the incidence of brain metastases in an orthotopic xenograft model. My work is currently focused on preclinical studies on the efficacy of combinatorial therapy in reducing circulating tumor cells (CTCs). Furthermore, I am determining if we can measure Axin 2 in clinical trial biopsy specimens as a proxy for drug efficacy. Both of these efforts support my ultimate goal to bring the combinational drug therapy into phase I clinical trial.